|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: TMEM219 |
Gene summary for TMEM219 |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | TMEM219 | Gene ID | 124446 |
| Gene name | transmembrane protein 219 | |
| Gene Alias | IGFBP-3R | |
| Cytomap | 16p11.2 | |
| Gene Type | protein-coding | GO ID | GO:0006915 | UniProtAcc | A0A024R618 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 124446 | TMEM219 | P48T-E | Human | Esophagus | ESCC | 3.28e-18 | 7.05e-01 | 0.0959 |
| 124446 | TMEM219 | P49T-E | Human | Esophagus | ESCC | 3.92e-13 | 1.93e+00 | 0.1768 |
| 124446 | TMEM219 | P52T-E | Human | Esophagus | ESCC | 3.03e-28 | 1.18e+00 | 0.1555 |
| 124446 | TMEM219 | P54T-E | Human | Esophagus | ESCC | 1.75e-30 | 1.06e+00 | 0.0975 |
| 124446 | TMEM219 | P56T-E | Human | Esophagus | ESCC | 1.27e-03 | 1.06e+00 | 0.1613 |
| 124446 | TMEM219 | P57T-E | Human | Esophagus | ESCC | 1.83e-44 | 1.34e+00 | 0.0926 |
| 124446 | TMEM219 | P61T-E | Human | Esophagus | ESCC | 1.90e-10 | 5.05e-01 | 0.099 |
| 124446 | TMEM219 | P62T-E | Human | Esophagus | ESCC | 2.31e-84 | 1.83e+00 | 0.1302 |
| 124446 | TMEM219 | P65T-E | Human | Esophagus | ESCC | 2.45e-32 | 8.83e-01 | 0.0978 |
| 124446 | TMEM219 | P74T-E | Human | Esophagus | ESCC | 4.78e-29 | 1.13e+00 | 0.1479 |
| 124446 | TMEM219 | P75T-E | Human | Esophagus | ESCC | 1.97e-52 | 1.54e+00 | 0.1125 |
| 124446 | TMEM219 | P76T-E | Human | Esophagus | ESCC | 3.94e-31 | 9.19e-01 | 0.1207 |
| 124446 | TMEM219 | P79T-E | Human | Esophagus | ESCC | 1.52e-15 | 4.82e-01 | 0.1154 |
| 124446 | TMEM219 | P80T-E | Human | Esophagus | ESCC | 3.03e-53 | 1.88e+00 | 0.155 |
| 124446 | TMEM219 | P82T-E | Human | Esophagus | ESCC | 2.76e-24 | 1.72e+00 | 0.1072 |
| 124446 | TMEM219 | P83T-E | Human | Esophagus | ESCC | 1.86e-47 | 1.79e+00 | 0.1738 |
| 124446 | TMEM219 | P84T-E | Human | Esophagus | ESCC | 3.25e-10 | 9.36e-01 | 0.0933 |
| 124446 | TMEM219 | P89T-E | Human | Esophagus | ESCC | 8.93e-21 | 1.76e+00 | 0.1752 |
| 124446 | TMEM219 | P91T-E | Human | Esophagus | ESCC | 1.10e-26 | 2.81e+00 | 0.1828 |
| 124446 | TMEM219 | P94T-E | Human | Esophagus | ESCC | 5.01e-03 | 1.31e+00 | 0.0879 |
| Page: 1 2 3 4 5 6 7 8 9 10 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Cervix |  | CC: Cervix cancer |
| HSIL_HPV: HPV-infected high-grade squamous intraepithelial lesions | ||
| N_HPV: HPV-infected normal cervix | ||
| Colorectum (GSE201348) |  | FAP: Familial adenomatous polyposis |
| CRC: Colorectal cancer | ||
| Colorectum (HTA11) |  | AD: Adenomas |
| SER: Sessile serrated lesions | ||
| MSI-H: Microsatellite-high colorectal cancer | ||
| MSS: Microsatellite stable colorectal cancer | ||
| Endometrium |  | AEH: Atypical endometrial hyperplasia |
| EEC: Endometrioid Cancer | ||
| Esophagus |  | ESCC: Esophageal squamous cell carcinoma |
| HGIN: High-grade intraepithelial neoplasias | ||
| LGIN: Low-grade intraepithelial neoplasias | ||
| Liver |  | HCC: Hepatocellular carcinoma |
| NAFLD: Non-alcoholic fatty liver disease | ||
| Oral Cavity |  | EOLP: Erosive Oral lichen planus |
| LP: leukoplakia | ||
| NEOLP: Non-erosive oral lichen planus | ||
| OSCC: Oral squamous cell carcinoma | ||
| Prostate |  | BPH: Benign Prostatic Hyperplasia |
| Skin |  | AK: Actinic keratosis |
| cSCC: Cutaneous squamous cell carcinoma | ||
| SCCIS:squamous cell carcinoma in situ | ||
| Thyroid |  | ATC: Anaplastic thyroid cancer |
| HT: Hashimoto's thyroiditis | ||
| PTC: Papillary thyroid cancer |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| Page: 1 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| TMEM219 | SNV | Missense_Mutation | c.462N>A | p.Ser154Arg | p.S154R | Q86XT9 | protein_coding | tolerated(0.14) | possibly_damaging(0.814) | TCGA-A7-A0CJ-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | cytoxan | SD | |
| TMEM219 | SNV | Missense_Mutation | c.463N>G | p.Gln155Glu | p.Q155E | Q86XT9 | protein_coding | tolerated(0.35) | possibly_damaging(0.479) | TCGA-A7-A0CJ-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | cytoxan | SD | |
| TMEM219 | SNV | Missense_Mutation | novel | c.649N>T | p.Gly217Cys | p.G217C | Q86XT9 | protein_coding | tolerated(0.07) | probably_damaging(1) | TCGA-AA-3811-01 | Colorectum | colon adenocarcinoma | Female | >=65 | III/IV | Unknown | Unknown | PD |
| TMEM219 | SNV | Missense_Mutation | c.143N>C | p.Leu48Pro | p.L48P | Q86XT9 | protein_coding | deleterious(0) | probably_damaging(0.999) | TCGA-AD-6964-01 | Colorectum | colon adenocarcinoma | Male | <65 | III/IV | Chemotherapy | folfox | PD | |
| TMEM219 | SNV | Missense_Mutation | novel | c.253N>A | p.Val85Ile | p.V85I | Q86XT9 | protein_coding | tolerated(0.22) | benign(0) | TCGA-A5-A0G2-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Unknown | Unknown | SD |
| TMEM219 | SNV | Missense_Mutation | novel | c.359N>A | p.Ser120Tyr | p.S120Y | Q86XT9 | protein_coding | tolerated(0.11) | possibly_damaging(0.628) | TCGA-A5-A0G2-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Unknown | Unknown | SD |
| TMEM219 | SNV | Missense_Mutation | rs761299676 | c.692N>A | p.Arg231Gln | p.R231Q | Q86XT9 | protein_coding | tolerated(0.06) | benign(0.003) | TCGA-A5-A1OF-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
| TMEM219 | SNV | Missense_Mutation | novel | c.451C>A | p.Leu151Ile | p.L151I | Q86XT9 | protein_coding | deleterious(0.03) | probably_damaging(0.994) | TCGA-AJ-A3NE-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
| TMEM219 | SNV | Missense_Mutation | rs766765480 | c.221N>A | p.Gly74Glu | p.G74E | Q86XT9 | protein_coding | tolerated(1) | benign(0.001) | TCGA-DF-A2KN-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | Unknown | I/II | Unknown | Unknown | SD |
| TMEM219 | SNV | Missense_Mutation | novel | c.300G>T | p.Arg100Ser | p.R100S | Q86XT9 | protein_coding | tolerated(0.15) | benign(0.022) | TCGA-21-1083-01 | Lung | lung squamous cell carcinoma | Male | >=65 | I/II | Unknown | Unknown | SD |
| Page: 1 2 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |